Ability of primary care health databases to assess medicinal products discussed by the European Union Pharmacovigilance Risk Assessment Committee

Robert Flynn (Lead / Corresponding author), Karin Hedenmalm, Tarita Murray-Thomas, Alexandra Pacurariu, Peter Arlett, Hilary Shepherd, Puja Myles, Xavier Kurz

Research output: Contribution to journalArticle

Abstract

This study measured the exposure to different categories of medicinal products discussed by the EU Pharmacovigilance Risk Assessment Committee from September to November 2018 in 4 electronic primary care health databases: IQVIA Medical Research Data-UK, IQVIA Medical Research Data-France, IQVIA Medical Research Data-Germany, and Clinical Practice Research Datalink Aurum, in the entire lifespan of each database until 31 August 2018. The assessment of 83 centrally authorized products and 45 nationally authorized products showed that coverage was better for products marketed for longer duration and worse for orphan drugs. The ability to detect associations against hypothetical comparators was better for more common events and for larger effect sizes. Coverage of advanced therapies was worse for those typically administered in a specialised rather than primary care setting. This study shows that to enable better informed regulatory decisions there is a need to access complementary data sources, particularly capturing secondary care prescribing.

Original languageEnglish
JournalClinical Pharmacology and Therapeutics
DOIs
Publication statusE-pub ahead of print - 18 Jan 2020

Fingerprint

Pharmacovigilance
European Union
Biomedical Research
Primary Health Care
Databases
Orphan Drug Production
Secondary Care
Information Storage and Retrieval
France
Germany
Research
Therapeutics

Cite this

Flynn, Robert ; Hedenmalm, Karin ; Murray-Thomas, Tarita ; Pacurariu, Alexandra ; Arlett, Peter ; Shepherd, Hilary ; Myles, Puja ; Kurz, Xavier. / Ability of primary care health databases to assess medicinal products discussed by the European Union Pharmacovigilance Risk Assessment Committee. In: Clinical Pharmacology and Therapeutics. 2020.
@article{6aa18ca6d57f4db28acfa959087960fc,
title = "Ability of primary care health databases to assess medicinal products discussed by the European Union Pharmacovigilance Risk Assessment Committee",
abstract = "This study measured the exposure to different categories of medicinal products discussed by the EU Pharmacovigilance Risk Assessment Committee from September to November 2018 in 4 electronic primary care health databases: IQVIA Medical Research Data-UK, IQVIA Medical Research Data-France, IQVIA Medical Research Data-Germany, and Clinical Practice Research Datalink Aurum, in the entire lifespan of each database until 31 August 2018. The assessment of 83 centrally authorized products and 45 nationally authorized products showed that coverage was better for products marketed for longer duration and worse for orphan drugs. The ability to detect associations against hypothetical comparators was better for more common events and for larger effect sizes. Coverage of advanced therapies was worse for those typically administered in a specialised rather than primary care setting. This study shows that to enable better informed regulatory decisions there is a need to access complementary data sources, particularly capturing secondary care prescribing.",
author = "Robert Flynn and Karin Hedenmalm and Tarita Murray-Thomas and Alexandra Pacurariu and Peter Arlett and Hilary Shepherd and Puja Myles and Xavier Kurz",
note = "No funding {\circledC} 2020 The Authors Clinical Pharmacology & Therapeutics {\circledC} 2020 American Society for Clinical Pharmacology and Therapeutics.",
year = "2020",
month = "1",
day = "18",
doi = "10.1002/cpt.1775",
language = "English",
journal = "Clinical Pharmacology & Therapeutics",
issn = "0009-9236",
publisher = "American Society for Clinical Pharmacology and Therapeutics",

}

Ability of primary care health databases to assess medicinal products discussed by the European Union Pharmacovigilance Risk Assessment Committee. / Flynn, Robert (Lead / Corresponding author); Hedenmalm, Karin; Murray-Thomas, Tarita; Pacurariu, Alexandra; Arlett, Peter; Shepherd, Hilary; Myles, Puja; Kurz, Xavier.

In: Clinical Pharmacology and Therapeutics, 18.01.2020.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ability of primary care health databases to assess medicinal products discussed by the European Union Pharmacovigilance Risk Assessment Committee

AU - Flynn, Robert

AU - Hedenmalm, Karin

AU - Murray-Thomas, Tarita

AU - Pacurariu, Alexandra

AU - Arlett, Peter

AU - Shepherd, Hilary

AU - Myles, Puja

AU - Kurz, Xavier

N1 - No funding © 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

PY - 2020/1/18

Y1 - 2020/1/18

N2 - This study measured the exposure to different categories of medicinal products discussed by the EU Pharmacovigilance Risk Assessment Committee from September to November 2018 in 4 electronic primary care health databases: IQVIA Medical Research Data-UK, IQVIA Medical Research Data-France, IQVIA Medical Research Data-Germany, and Clinical Practice Research Datalink Aurum, in the entire lifespan of each database until 31 August 2018. The assessment of 83 centrally authorized products and 45 nationally authorized products showed that coverage was better for products marketed for longer duration and worse for orphan drugs. The ability to detect associations against hypothetical comparators was better for more common events and for larger effect sizes. Coverage of advanced therapies was worse for those typically administered in a specialised rather than primary care setting. This study shows that to enable better informed regulatory decisions there is a need to access complementary data sources, particularly capturing secondary care prescribing.

AB - This study measured the exposure to different categories of medicinal products discussed by the EU Pharmacovigilance Risk Assessment Committee from September to November 2018 in 4 electronic primary care health databases: IQVIA Medical Research Data-UK, IQVIA Medical Research Data-France, IQVIA Medical Research Data-Germany, and Clinical Practice Research Datalink Aurum, in the entire lifespan of each database until 31 August 2018. The assessment of 83 centrally authorized products and 45 nationally authorized products showed that coverage was better for products marketed for longer duration and worse for orphan drugs. The ability to detect associations against hypothetical comparators was better for more common events and for larger effect sizes. Coverage of advanced therapies was worse for those typically administered in a specialised rather than primary care setting. This study shows that to enable better informed regulatory decisions there is a need to access complementary data sources, particularly capturing secondary care prescribing.

U2 - 10.1002/cpt.1775

DO - 10.1002/cpt.1775

M3 - Article

C2 - 31955404

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

SN - 0009-9236

ER -